Condition

Refractory Osteosarcoma clinical trials and research

• 7Clinical trials
• 2Countries

Newest Refractory Osteosarcoma clinical trials

All recruiting trials (7)

• FH-FOLR1 CAR T cell therapy for advanced or recurrent osteosarcoma

  This trial will test whether FH-FOLR1 CAR T cells are safe and what dose works best in people aged 1–75 with advanced, recurrent, or treatment-resistant osteosarcoma.

  Recruiting Phase 1 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07227571

• NKG2D.zeta-NK cells plus C7R.GD2.CAR-T cells for relapsed or refractory neuroblastoma or osteosarcoma

  This study tests a combination of modified NK cells and CAR-T cells to see if it can safely help patients with GD2-expressing relapsed or refractory neuroblastoma or osteosarcoma.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT07211737

• Tegavivint plus gemcitabine for relapsed or refractory osteosarcoma

  This trial tests whether adding tegavivint to gemcitabine is safe and can help people whose osteosarcoma has come back or not responded to prior treatment.

  Recruiting at 2 sites Phase 1 Emory University · Atlanta, Georgia and 1 other locations · NCT07144254

• Using expanded gamma delta T cells with chemotherapy for treating relapsed neuroblastoma and osteosarcoma

  This study is testing if a new treatment using special immune cells along with chemotherapy can help children with relapsed neuroblastoma and osteosarcoma feel better and improve their chances of recovery.

  Recruiting Phase 1 Emory University · Atlanta, Georgia · NCT05400603

• Combining atezolizumab and cabozantinib for treating recurrent or metastatic osteosarcoma in adolescents and young adults

  This study tests if combining two medications, atezolizumab and cabozantinib, can help adolescents and young adults with recurrent or metastatic osteosarcoma live longer and feel better.

  Recruiting at 2 sites Phase 2 M.D. Anderson Cancer Center · Boston, Massachusetts and 1 other locations · NCT05019703

• Onivyde combined with talazoparib or temozolomide for children and young adults with recurrent solid tumors and Ewing sarcoma

  This will test whether adding talazoparib or temozolomide to Onivyde helps children and young adults whose solid tumors or Ewing sarcoma have come back.

  Recruiting at 8 sites Phase 1/2 St. Jude Children's Research Hospital · Palo Alto, California and 9 other locations · NCT04901702

• Tegavivint treatment for recurrent or refractory solid tumors in children

  This study tests if a new intravenous medication called tegavivint can help children with tough-to-treat solid tumors, like Ewing sarcoma and desmoid tumors, by finding the right dose and seeing how well it works.

  Recruiting at 19 sites Phase 1/2 Children's Oncology Group · Birmingham, Alabama and 20 other locations · NCT04851119

Related topics

Quick answers

How many Refractory Osteosarcoma clinical trials are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in United States (7 trials), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 4, Phase 1/2: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →